Latest Post

Will a new tax and informal IRP network help France negotiate a lower price for Sovaldi?

Will a new tax and informal IRP network help France negotiate a lower price for Sovaldi?

While an increasing number of new HCV treatments gain approval for marketing authorisation in Europe, EU member states are looking at ways to ensure that commercialisation of new-generation hepatitis C virus (HCV) treatments does not defeat the efforts of containing national expenditure. Since the marketing of Gilead Sciences’ Sovaldi (sofosbuvir) in January 2014, two other … Continue reading

Recent Posts

Pages

Enter your email address to follow this blog and receive notifications of new posts by email.

Download extract from IHS Flexible Pricing strategies multi client study
Drug Price Erosion Multi Client Study extract download

About This Blog

In this blog, our experts share regular insights on the global life sciences industry. Join us as we look at issues in healthcare policy, market access, pricing and reimbursement and R&D. Comments are welcome!
40 countries covered. Download a sample chapter on Brazil
Download a complimentary white paper on market-access risk ratings
Download a sample of the primary research and analysis on French P&R reform

Follow IHS Life Sciences on Twitter

Follow

Get every new post delivered to your Inbox.

Join 305 other followers